Kazia Therapeutics has announced that the GBM AGILE study in glioblastoma has opened recruitment to the paxalisib arm in Europe.

Kazia Therapeutics marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased focus on childhood brain cancer among policymakers.

Kazia CEO Dr James Garner tells Andrew Scott about the company's quarterly achievements, including data the company presented at the American Association of Cancer Research (AACR) conference on the use of its asset paxalisib in a rare, aggressive childhood cancer. It has been a busy quarter for the company on the trials front, and news for investors is good too, with the company introducing an at-the-market financing facility in the US - a quick and efficient way of transacting on biotech shares.